...A. 2025 is off to a strong start, and we have already achieved several important milestones, including the national coverage decision for our transcatheter tricuspid valve EVOQUE, CE mark approval of our SAPIEN M3 mitral valve replacement system, the release of eight-year data confirming the long-term durability of our proprietary resilient tissue. B. And just last week, the FDA approval of the Edward SAPIEN 3 platform to treat asymptomatic patients. C. The fourth item of business is the approval of the amendment and restatement of our 2001 Employee Stock Purchase Plan for US employees to increase the total number of shares of common stock available for issuance by 4,200,000 shares. D. The fifth item of business is the approval of the amendment and restatement of our 2001 Employee Stock Purchase Plan for international employees to increase the total number of shares of common stock available for issuance by 1,460,000 shares....
